ARF6 and neoplasm: These results suggest that inhibition of the ARF6-AMAP1 pathway on its own alleviates some of the immune evasiveness of KPC tumor cells, but as we have previously shown [23], inhibition of this pathway together with anti-PD-1 antibody treatment results in therapeutic synergy.